Russell Investments Group Ltd. Has $710,000 Stock Holdings in Dyne Therapeutics, Inc. $DYN

Key Points

• Russell Investments Group Ltd. reduced its stake in Dyne Therapeutics by 41.9% during the first quarter, now holding 67,877 shares valued at approximately $710,000.
• CEO John Cox bought 100,000 shares of Dyne Therapeutics for $911,000, increasing his ownership by 70.33%.
• Analyst ratings for Dyne Therapeutics vary, with price targets ranging from $9.00 to $50.00, resulting in a consensus rating of "Buy."

Russell Investments Group Ltd. lowered its holdings in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 41.9% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 67,877 shares of the company's stock after selling 48,852 shares during the period. Russell Investments Group Ltd. owned 0.06% of Dyne Therapeutics worth $710,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the company. GF Fund Management CO. LTD. purchased a new stake in shares of Dyne Therapeutics during the 4th quarter worth $50,000. GAMMA Investing LLC boosted its stake in Dyne Therapeutics by 837.5% in the 1st quarter. GAMMA Investing LLC now owns 2,625 shares of the company's stock worth $251,000 after buying an additional 2,345 shares during the last quarter. Neo Ivy Capital Management purchased a new position in shares of Dyne Therapeutics in the 4th quarter worth $205,000. Hsbc Holdings PLC increased its position in shares of Dyne Therapeutics by 45.5% in the fourth quarter. Hsbc Holdings PLC now owns 13,354 shares of the company's stock worth $316,000 after acquiring an additional 4,178 shares in the last quarter. Finally, Arizona State Retirement System boosted its holdings in Dyne Therapeutics by 9.2% in the 1st quarter. Arizona State Retirement System now owns 17,501 shares of the company's stock worth $183,000 after acquiring an additional 1,481 shares during the period. Hedge funds and other institutional investors own 96.68% of the company's stock.

Insiders Place Their Bets

In other Dyne Therapeutics news, CEO John Cox bought 100,000 shares of Dyne Therapeutics stock in a transaction on Monday, July 14th. The stock was purchased at an average cost of $9.11 per share, for a total transaction of $911,000.00. Following the completion of the purchase, the chief executive officer directly owned 242,179 shares of the company's stock, valued at $2,206,250.69. The trade was a 70.33% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 14.14% of the company's stock.

Dyne Therapeutics Stock Down 1.8%

DYN traded down $0.24 during trading on Thursday, reaching $13.24. 1,751,830 shares of the stock traded hands, compared to its average volume of 2,419,008. The stock's 50-day simple moving average is $10.70 and its two-hundred day simple moving average is $11.16. The company has a debt-to-equity ratio of 0.17, a current ratio of 16.83 and a quick ratio of 16.83. Dyne Therapeutics, Inc. has a fifty-two week low of $6.36 and a fifty-two week high of $37.08. The stock has a market cap of $1.88 billion, a price-to-earnings ratio of -3.43 and a beta of 1.10.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last posted its quarterly earnings results on Monday, July 28th. The company reported ($0.97) earnings per share for the quarter, topping analysts' consensus estimates of ($0.99) by $0.02. As a group, equities research analysts expect that Dyne Therapeutics, Inc. will post -3.44 EPS for the current year.

Analyst Ratings Changes

DYN has been the subject of several research analyst reports. Sanford C. Bernstein assumed coverage on Dyne Therapeutics in a report on Tuesday, June 24th. They issued a "market perform" rating and a $13.00 price objective for the company. Royal Bank Of Canada reduced their price objective on shares of Dyne Therapeutics from $25.00 to $23.00 and set an "outperform" rating for the company in a research note on Tuesday, July 29th. Stifel Nicolaus dropped their target price on shares of Dyne Therapeutics from $66.00 to $36.00 and set a "buy" rating on the stock in a research report on Thursday, July 31st. Evercore ISI restated an "outperform" rating on shares of Dyne Therapeutics in a report on Friday, July 11th. Finally, Chardan Capital decreased their price objective on shares of Dyne Therapeutics from $50.00 to $38.00 and set a "buy" rating for the company in a research note on Tuesday, July 29th. Three equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, Dyne Therapeutics has an average rating of "Buy" and an average target price of $34.07.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.